Glenmark Pharmaceuticals has received shareholders' approval to raise up to $200 million (about Rs 1,413 crore) through issuance of debt securities. The proposal was approved at the company's annual general meeting held on September 27, 2019.
According to the proposal, the company planning to raise up to $200 million in Indian and/or international market through bonds, debentures or other debt securities in one or more tranches.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.80 |
| Dr. Reddys Lab | 1238.75 |
| Cipla | 1238.25 |
| Zydus Lifesciences | 942.95 |
| Lupin | 2331.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: